Recruiting

GRID Therapy

Sponsor:

Sir Mortimer B. Davis - Jewish General Hospital

Code:

NCT02333110

Conditions

Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

spatially fractionated radiation therapy

Study Details

Brief summary:

Palliative radiation therapy represents 40% of the on-going radiation at the Jewish General Hospital. In a traditional palliative radiation treatment to bulky or radioresistant tumors, radiotherapy schema varies from 24 to 30 Gys given in 3 to 10 fractions, depending on the tumor size, tumor location and tumor pathology. However, for many patients this treatment involves considerable toxicity, travel and time spent at the hospital. Spatially fractionated radiation (SFR) is an alternative technique that consists in delivering one single treatment, given through a grid containing holes. The present study is proposing to validate SFR as a safe and effective mean to palliate patients with symptomatic bulky tumors (more than 8 cm) or with tumors known to be resistant to radiation.

Conditions

Patients With Symptomatic or Bulky Tumors (More Than 8 cm) or With Tumors Resistant to Radiation

Study ID

NCT02333110

Start date

Jan, 2015

Status verified date

May, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patient with histologically or cytologically confirmed malignancy. All malignant histologies/cytologies are eligible.
  • Patient with bulky tumor (larger than 8cm), or with a tumor known to be resistant to radiation (eg. Melanoma, hypernephroma, sarcoma), or with a tumor previously irradiated with a palliative intent requiring more than 1 fraction of radiation
  • Patient planned to undergo palliative radiation therapy treatments to one of the following 5 sites: extremities, neck, chest, abdomen and pelvis
  • WHO performance status of 0-2
  • Aged 18 years or older
  • Ability to sign and understand an informed consent form

Exclusion Criteria:

  • Potentially curable patient
  • Previous palliative radiation with hypofractionation
  • Tumor located near the spinal cord or in the brain
  • Pregnant or nursing woman

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: GRID radiation therapy

A single dose of 15-20Gys of spatially fractionated radiation therapy

Interventions

spatially fractionated radiation therapy

A single dose of 15-20Gys of spatially fractionated radiation therapy

Primary outcome measure

  • Symptom relief, as measured using the CTCAE grading system (v4.0) and pain questionnaire [ Time Frame: 3 months post treatment ]

Central Contacts and Locations

Central contacts

Luciana Poggi, PhD

514-340-8222luciana.poggi.trinidad.ccomtl@ssss.gouv.qc.ca

Locations

Sir Mortimer Jewish General Hospital

Recruiting

Montreal, Quebec, Canada, H3T 1E2

Contacts

Harielle Lamarre, BSc

514-340-8222hlamarre@jgh.mcgill.ca

More Information

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Last update posted

May 12, 2026

Last verified

May, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Sir Mortimer B. Davis - Jewish General Hospital on 2026-05-12.